Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

CD68+ Tumor Associated Macrophages Have Significant Impact on Therapeutic Outcome in Newly Diagnosed Multiple Myeloma (MM)

Ricardo Parrondo, MD, Muhamad Alhaj Moustafa, MD, Han W. Tun, MD, Liuyan Jiang, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-139835

Published: 2020

Journal Articles

A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-138896

Published: 2020

Journal Articles

Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL)

Madiha Iqbal, MBBS, Yennifer Gil, Jonas Paludo, MD, Allison C. Rosenthal, D.O., Zhou Li, MS, Manuel Beltran, David J. Inwards, MD, Luis F. Porrata, MD, Ivana Micallef, MD, Jose C Villasboas, MD, Patrick B. Johnston, Stephen M. Ansell, MD PhD, Craig B. Reeder, MD, Hemant S. Murthy, MD, Vivek Roy, MD, James M. Foran, MD, Han W. Tun, MD, Mohamed A. Kharfan-Dabaja, MDMBA, Ernesto Ayala, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136332

Published: 2020

Journal Articles

A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies

Grzegorz S. Nowakowski, MD, Lori A. Leslie, MD, Erel Joffe, MD MSc, Allison C. Rosenthal, D.O., Matthew A. Lunning, DO, FACP, Krish Patel, MD, Monica Mead, MD BS, Daniel J. Landsburg, MD, Timothy S. Fenske, MD, Radhakrishnan Ramchandren, Praveen Ramakrishnan Geethakumari, MD MS, Alan Skarbnik, MD, Elizabeth Martinez, PhD DHSC, MSN, Christopher Lieberman, Reinhard von Roemeling, MD, Han W. Tun, MD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-140884

Published: 2020

Journal Articles

Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study

Grzegorz S. Nowakowski, MD, Lori A. Leslie, MD, Anas Younes, Allison C. Rosenthal, D.O., Matthew A. Lunning, DO, FACP, Krish Patel, MD, Daniel J. Landsburg, MD, Elizabeth Martinez, PhD DHSC, MSN, Reinhard von Roemeling, MD, Christopher Lieberman, Han W. Tun, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-140857

Published: 2020

Journal Articles

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

Anas Younes, MD, Grzegorz Nowakowski, MD, Allison C. Rosenthal, DO, Lori A. Leslie, MD, Han W. Tun, MD, Matthew A. Lunning, DO, FACP, Iris Isufi, MD, Robert Martell, MD PhD, Krish Patel, MD

Blood (2019) 134 (Supplement_1): 5327.

https://doi.org/10.1182/blood-2019-131851

Published: 2019

Journal Articles

Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)

Blood (2019) 134 (Supplement_1): 5343.

https://doi.org/10.1182/blood-2019-126594

Published: 2019

Journal Articles

Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR

Zaid Abdel Rahman, MD, Nicole Gannon, PA-C, Megan Melody, MD, Paul Muniz, RN, Ernesto Ayala, MD, Vivek Roy, MD, Lisa Brumble, Sikander Ailawadhi, MD, Taimur Sher, MD, James M. Foran, MD, Hemant S. Murthy, MD, Han W. Tun, MD, Candido E. Rivera, MD, Asher A. Chanan-Khan, MD, Abba C. Zubair, MD PhD, Mohamed A Kharfan-Dabaja, MDMBA

Blood (2019) 134 (Supplement_1): 5610.

https://doi.org/10.1182/blood-2019-122067

Published: 2019

Journal Articles

Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD

Blood (2019) 134 (Supplement_1): 2809.

https://doi.org/10.1182/blood-2019-129391

Published: 2019

Journal Articles

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Jose C Villasboas, MD, Craig B. Reeder, MD, Han W. Tun, MD, Nancy L Bartlett, MD, Elad Sharon, MD MPH, Betsy Laplant, MS, Alex A Adjei, MD PhD, Justin Kline, MD, Francisco J. Hernandez-Ilizaliturri, MD, Farrukh T. Awan, MD, Sumana Devata, MD, Aleksandr Lazaryan, MDPhDMPH, Lawrence E Morris, MD, Stephen M Ansell, MD PhD, Catherine Diefenbach, MD

Blood (2019) 134 (Supplement_1): 1591.

https://doi.org/10.1182/blood-2019-130449

Published: 2019

Journal Articles

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD

Blood (2019) 134 (Supplement_1): 1544.

https://doi.org/10.1182/blood-2019-130384

Published: 2019

Journal Articles

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

Blood (2019) 134 (Supplement_1): 810.

https://doi.org/10.1182/blood-2019-126192

Published: 2019

Journal Articles

DA.R-EPOCH Vs. R-CHOP for High-Risk Diffuse Large B- Cell Lymphoma: The Mayo Clinic Florida Experience

Bhagirathbhai Dholaria, MBBS, Prakash Vishnu, MD FACP, Vivek Roy, MD, Han W Tun, MD, Taimur Sher, MD, Candido E. Rivera, MD, Sikander Ailawadhi, Nancy Diehl, David O. Hodge, MS, Yenni Alejandro Moreno-Vanegas

Blood (2017) 130 (Supplement 1): 1572.

https://doi.org/10.1182/blood.V130.Suppl_1.1572.1572

Published: 2017

Journal Articles

Preclinical Evaluation of Ibrutinib for Central Nervous System Lymphoma

Frederic Pouzoulet, PhD, Keyvan Rezai, PhD, Zhimin Li, PhD, Qiu Yushi, Han W Tun, MD, Dalila Labiod, Engeneer, Sarah Bonnet-Boissinot, Engineer, Carole Soussain, MD PhD

Blood (2016) 128 (22): 4170.

https://doi.org/10.1182/blood.V128.22.4170.4170

Published: 2016

Journal Articles

Therapy with Ibritumomab Tiuxetan (Zevalin ® ) in Patients with Previously Untreated and Relapsed Low Grade Follicular Lymphoma: The Mayo Clinic Florida Experience, 2000-2016

Aixa Elena Soyano, MD, Ryan D Frank, MS, Han W Tun, MD, Jennifer Peterson, MD

Blood (2016) 128 (22): 5324.

https://doi.org/10.1182/blood.V128.22.5324.5324

Published: 2016

Journal Articles

Outcome Disparities in T-Cell Non-Hodgkin Lymphoma and the Lack of Significant Improvement over the Years: A SEER Database Review

Jennifer A Crozier, MD, Taimur Sher, MD, Dongyun Yang, PhD, Abhisek Swaika, MBBS, James M. Foran, MD, Han W Tun, MD, Gerardo Colon-Otero, MD, Asher Alban Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2014) 124 (21): 2597.

https://doi.org/10.1182/blood.V124.21.2597.2597

Published: 2014

Journal Articles

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).

Craig B. Reeder, MD, Michel K. Gornet, MD, Thomas M. Habermann, MD, Stephen M. Ansell, MD, PhD, Ivana N. Micallef, MD, Luis F. Porrata, MD, Patrick B. Johnston, MD, PhD, Matthew J. Maurer, MS, Betsy LaPlant, MS, Brian Kabat, MS, David J. Inwards, MD, Joseph P. Colgan, MD, Timothy Call, MD, Svetomir Markovic, MD, PhD, Clive S. Zent, MD, Steven R. Zeldenrust, MD, PhD, Han W. Tun, MD, Thomas E. Witzig, MD

Blood (2007) 110 (11): 121.

https://doi.org/10.1182/blood.V110.11.121.121

Published: 2007

NARROW

CD68+ Tumor Associated Macrophages Have Significant Impact on Therapeutic Outcome in Newly Diagnosed Multiple Myeloma (MM)

A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma

Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL)

A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies

Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)

Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR

Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

DA.R-EPOCH Vs. R-CHOP for High-Risk Diffuse Large B- Cell Lymphoma: The Mayo Clinic Florida Experience

Preclinical Evaluation of Ibrutinib for Central Nervous System Lymphoma

Therapy with Ibritumomab Tiuxetan (Zevalin ® ) in Patients with Previously Untreated and Relapsed Low Grade Follicular Lymphoma: The Mayo Clinic Florida Experience, 2000-2016

Outcome Disparities in T-Cell Non-Hodgkin Lymphoma and the Lack of Significant Improvement over the Years: A SEER Database Review

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only